Artiva Biotherapeutics, Inc. Common Stock (ARTV)vsMerck & Company Inc (MRK)
ARTV
Artiva Biotherapeutics, Inc. Common Stock
$11.27
-2.68%
HEALTHCARE · Cap: $563.14M
MRK
Merck & Company Inc
$128.58
+0.16%
HEALTHCARE · Cap: $316.14B
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
ARTV
Avoid20
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARTV.
Margin of Safety
-58.0%
Fair Value
$81.23
Current Price
$128.58
$47.35 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARTV
The strongest argument for ARTV centers on Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ARTV
The primary concerns for ARTV are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ARTV carries more volatility with a beta of 2.18 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artiva Biotherapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a promising pipeline targeting both hematologic and solid tumors, the company is at the forefront of innovation in the dynamic field of immuno-oncology. Leveraging its commitment to scientific excellence and strategic collaborations, Artiva is strategically positioned to advance its clinical candidates, thereby significantly improving patient outcomes in the fight against cancer. As it progresses through crucial clinical trials, the company's innovative approach holds the potential to reshape cancer treatment paradigms.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?